Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: SCAR Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of Knotless Suture for Closure of Total Hip and Knee Arthroplasties

NCT00834483
View directory record Official record
Conditions
Knee Osteoarthritis, Hip Osteoarthritis
Interventions
Knotless suture for wound closure, Layered traditional wound closure (monocryl)
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

NCT02855944
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Chemotherapy, Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Denver, Colorado • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 20, 2026, 2:18 PM EDT
Not listed Not applicable Interventional

Pulmonary Vein Antrum Isolation (PVAI) Plus Scar Homogenization and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation

NCT01672138
View directory record Official record
Conditions
Persistent Atrial Fibrillation, Long-standing Persistent Atrial Fibrillation
Interventions
Pulmonary Vein Antrum Isolation, scar homogenization, Non-PV triggers ablation
Procedure
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Not applicable Interventional

"A Clinical Study Investigating the Effectiveness of OTC Scar-management Modalities"

NCT04169490
View directory record Official record
Conditions
Scar, Keloid, Hypertrophic Scar, Cicatrix
Interventions
Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer, Active Comparator Onion Skin Extract Gel (Mederma), Active Comparator Silicone Gel (Kelo-Cote), Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer
Other
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 20, 2026, 2:18 PM EDT
Not listed Not applicable Interventional

Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata

NCT03078686
View directory record Official record
Conditions
Alopecia Areata, Scarring Alopecia
Interventions
tSVF by lipoaspiration, PRP Concentration, Emulsification tSVF, cSVF isolation and concentration, cSVF in Normal Saline IV
Procedure
Lead sponsor
Regeneris Medical
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Irvine, California • North Attleboro, Massachusetts • Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Early Phase 1 Interventional

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

NCT03346668
View directory record Official record
Conditions
Scarring Alopecia, Frontal Fibrosing Alopecia, Lichen Planopilaris, Central Centrifugal Cicatricial Alopecia, Central Centrifugal Scarring Alopecia
Interventions
Topical gabapentin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 20, 2026, 2:18 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Restylane Silk Acne Scar Efficacy Evaluation Study

NCT02955381
View directory record Official record
Conditions
Acne, Acne Scars, AdverseEvent
Interventions
Restylane Silk, 1.0 ml, Saline, 1.0 ml
Device
Lead sponsor
Schweiger Dermatology, PLLC
Industry
Eligibility
22 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Treatment of Surgical Scars Using the Pulsed Dye Laser

NCT00970671
View directory record Official record
Conditions
Scar, Laser Therapy
Interventions
Laser treatment with Purpuric settings, Laser treatment with Nonpurpuric settings, No treatment
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

NCT00450775
View directory record Official record
Conditions
Scars
Interventions
Dermatix Q
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery

NCT06919809
View directory record Official record
Conditions
Wound Healing After MMS Surgery, BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Melanoma In Situ
Interventions
A microsurfaced ADM (acellular dermal matrix)
Device
Lead sponsor
McGuire Institute
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockwall, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

NCT04827875
View directory record Official record
Conditions
Keloid, Scar, Incision, Excision Margin
Interventions
AIV001
Drug
Lead sponsor
AiViva BioPharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Encinitas, California • Coral Gables, Florida • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 20, 2026, 2:18 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin

NCT00276419
View directory record Official record
Conditions
Breast Pain, Non-cyclical Mastalgia, Surgical Scar-Related Breast Pain
Interventions
Diclofenac, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 20, 2026, 2:18 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Mechanical Coring to Achieve Directional Skin Tightening

NCT04910945
View directory record Official record
Conditions
Skin Tightening, Healthy Volunteers
Interventions
VENUS AIME (RoboCor)
Device
Lead sponsor
Venus Concept
Industry
Eligibility
30 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Los Altos, California • San Jose, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 20, 2026, 2:18 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The MIRIA Acne Scar Study

NCT05597267
View directory record Official record
Conditions
Acne Scars - Mixed Atrophic and Hypertrophic
Interventions
MIRIA Laser
Device
Lead sponsor
AVAVA, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Miami, Florida • Waltham, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)

NCT01077921
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Laura M. De Castro, MD
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 20, 2026, 2:18 PM EDT
Terminated Not applicable Interventional

A Randomized Clinical Study Comparing Two Closure Techniques of Excised Keloids

NCT00519493
View directory record Official record
Conditions
Keloid
Interventions
Suture, Clozex
Procedure · Device
Lead sponsor
University of Miami
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 20, 2026, 2:18 PM EDT
Recruiting Phase 4 Interventional

Remimazolam vs Propofol in Laser Burn Cases

NCT07213544
View directory record Official record
Conditions
Burn Scar, Hypertrophic Scarring, Procedural Sedation
Interventions
Remimazolam besylate, Propofol
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes Following Intralesional Corticosteroid Injections

NCT03630198
View directory record Official record
Conditions
Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions
Corticosteroid with lidocaine, Corticosteroid with normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

Corticosteroids for Children With Febrile Urinary Tract Infections

NCT01391793
View directory record Official record
Conditions
Acute Urinary Tract Infection, Urinary Tract Infection
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
2 Months to 6 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids

NCT05128383
View directory record Official record
Conditions
Keloid
Interventions
Dupilumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction

NCT01559922
View directory record Official record
Conditions
Atrophic Acne Scar
Interventions
Normal Saline, Artefill
Drug · Device
Lead sponsor
Suneva Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Beverly Hills, California • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 20, 2026, 2:18 PM EDT
Withdrawn Phase 2 Interventional

Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars

NCT00620737
View directory record Official record
Conditions
Restrictive Burn Scars of Joint Area
Interventions
Autologous Human Fibroblasts (Isolagen TherapyTM), Placebo
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
3
States / cities
Boston, Massachusetts • East Meadow, New York • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2012 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cranberry Juice and Cardiovascular Disease

NCT01295684
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Cranberry juice, Placebo
Other
Lead sponsor
United States Department of Agriculture (USDA)
Federal
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2011 · Synced Oct 20, 2026, 2:18 PM EDT
Terminated Not applicable Interventional Results available

DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery

NCT00387829
View directory record Official record
Conditions
Spinal Injuries, Adhesions
Interventions
DuraGen Plus Adhesion Barrier Matrix
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
36
States / cities
Mobile, Alabama • Beverly Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 20, 2026, 2:18 PM EDT